The research team, led by Sam Salek of the University of Hertfordshire together with Jeffrey Johns, Faraz M. Ali and Andrew Y. Finlay of Cardiff University, along with colleagues in Norway and Germany, analyzed data from 3,408 dermatology outpatients recruited across 13 European countries: Belgium, Denmark, France, Germany, Hungary, Italy, the Netherlands, Norway, Poland, Russia, Spain, Turkey and the United Kingdom. The dataset originated in a large multicenter cross-sectional study in which 250 consecutive adult patients were enrolled at each participating clinic. Every patient completed the DLQI in their own validated national language version, alongside the generic EQ-5D-3L health questionnaire and a physician-assessed severity rating. Crucially, the analysis included only patients with complete DLQI responses, eliminating missing-data ambiguity from the statistical models.

The central technical question was one of measurement invariance, the psychometric property that determines whether an instrument measures the same underlying construct in the same way across different groups. The researchers applied a hierarchical testing framework using multiple-group confirmatory factor analysis, or MGCFA. At the first level, configural invariance asks whether the same factor structure holds in every country, meaning respondents everywhere conceptualize the construct similarly. At the second level, metric invariance tests whether factor loadings, the strengths of the relationships between individual items and the latent quality-of-life factor, are equal across groups. Only if those hold does scalar invariance, equality of item thresholds, come into play, and it is scalar invariance that licenses direct comparison of mean scores between countries. Each successive level imposes stricter constraints, and each was tested against established fit criteria from the COSMIN consensus framework.

The first major finding was that the DLQI behaves as essentially unidimensional in every one of the 13 language versions. Confirmatory factor analysis using a single-factor model produced unscaled comparative fit index and Tucker-Lewis index values above 0.97 in all countries, comfortably exceeding the COSMIN threshold of 0.95. This matters because unidimensionality is the fundamental precondition for summing ten items into one interpretable number. If the items tapped several unrelated constructs, the total score would be statistically unstable and conceptually ambiguous. The team used polychoric correlations, which are designed for ordinal Likert-type data rather than the continuous, normally distributed data assumed by Pearson correlation, and found all inter-item correlations above 0.42 with none exceeding 0.85, ruling out both weak relationships and item redundancy. Contemporary measurement science accepts that perfectly unidimensional health measures are essentially nonexistent; what is required is a dominant general factor strong enough that the composite score behaves like a measure of one construct, and the DLQI cleared that bar in every country.

The multigroup analysis then delivered the study’s most consequential result. Configural invariance held across the 12 countries included in the MGCFA models, confirming that all translations conceptualize the same construct. Metric invariance also held, with equality of factor loadings demonstrated within the fit-change thresholds recommended by measurement methodologist F.F. Chen, meaning the items are equally related to the latent factor everywhere. But full scalar invariance was not achieved: the drop in CFI of 0.03 and rise in RMSEA of 0.023 exceeded the accepted limits of 0.01 and 0.015 respectively. In practical terms, this means that directly comparing average DLQI scores between countries is not statistically supported by the current evidence, even though the instrument measures the same construct everywhere.

There was, however, a partial rescue. By relaxing the equality constraint on a single threshold of DLQI item 7, which concerns treatment difficulties, the researchers achieved partial scalar invariance. The culprit threshold was clearly identifiable: modification indices flagged it with a chi-squared value of 39.7 and a p-value below 0.0001, and plots of thresholds by country revealed that Russia and Turkey were outliers for that specific item parameter. This pattern is far from unusual in cross-national psychometrics. The authors note that a study of the Satisfaction With Life Scale across 65 nations achieved configural and metric but not full scalar invariance, that the Quality of Life Enjoyment and Satisfaction Questionnaire showed 12 of 14 items non-invariant across ten countries, and that a systematic review of 75 studies using personality measures found none achieved scalar or strict invariance across cultural groups. Against that backdrop, the DLQI’s near-miss is a strong performance.

The study also confronted a well-known statistical subtlety. The weighted least squares mean and variance adjusted estimator, or WLSMV, used because DLQI data are ordinal and skewed with floor effects, is known to inflate the root mean square error of approximation, particularly in multigroup settings with sparse response categories. The scaled RMSEA of 0.089 in the baseline model looked alarming, but an alternative unweighted least squares estimator produced a value of 0.061, within acceptable limits. Similarly, elevated standardized root mean square residuals in France, Turkey and Belgium were traced to skewed data and sparse response categories rather than genuine model failure. France, which contributed only 107 patients and had no responses in two response categories of the final item, was excluded from the multigroup models for technical reasons. These methodological caveats illustrate why modern psychometric validation demands more than a glance at a single fit index.

Beyond the invariance testing, the study confirmed that the DLQI does what clinicians actually need it to do: distinguish patients of different disease severity. Known-group analysis using the Jonckheere-Terpstra non-parametric test, which detects ordered trends across groups, showed significant differentiation of DLQI scores by physician-assessed severity in every single country, with most comparisons significant at p less than 0.001. Spearman correlations between DLQI scores and the EQ-5D-3L dimensions, including mobility, self-care, usual activities, pain and anxiety-depression, were all significant and in the expected directions, with the strongest associations around 0.4. Mean DLQI scores ranged from 3.46 in Belgium to 10.69 in Poland, reflecting genuine differences in the disease mix across clinics, from psoriasis and acne to venous ulcers, non-melanoma skin cancer and hidradenitis suppurativa, rather than measurement artifacts.

The upshot for international dermatology research is nuanced but constructive. The DLQI can be trusted to measure the same quality-of-life construct across these 13 European languages, and within any country its scores are valid and clinically meaningful. Researchers planning multinational trials, however, should be cautious about pooling or directly comparing mean scores across countries without accounting for the demonstrated threshold non-invariance, and the authors point toward Bayesian approximate invariance methods, alignment techniques and item-level differential item functioning analyses as promising next steps. The team also cautions that European findings may not generalize to Asian, Middle Eastern or African cultural contexts, and that historical records of cognitive debriefing for some translations are incomplete. For an instrument that has shaped treatment thresholds, guideline decisions and drug trial endpoints for three decades, this study provides the kind of forensic self-examination that few patient-reported measures have undergone, and it largely vindicates the questionnaire’s global role while drawing a precise boundary around where cross-country score comparisons can and cannot be trusted.

Subject of Research: Cross-cultural measurement equivalence and psychometric validation of the Dermatology Life Quality Index across 13 European countries

Article Title: Equivalence of measurement properties of the Dermatology Life Quality Index (DLQI) across 13 European countries

Article References: Salek, S., Johns, J., Ali, F. M., Dalgard, F. J., Kupfer, J., & Finlay, A. Y. (2026). Equivalence of measurement properties of the Dermatology Life Quality Index (DLQI) across 13 European countries. Archives of Dermatological Research, 318(1), Article 518. https://doi.org/10.1007/s00403-026-04877-0

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04877-0

Keywords: Dermatology Life Quality Index, DLQI, measurement invariance, psychometrics, confirmatory factor analysis, patient-reported outcomes, quality of life, dermatology, cross-cultural validation, unidimensionality, MGCFA, Europe

The fix, called the DLQI-Relevant or DLQI-R score, was proposed by Hungarian health economists led by Ferenc Rencz and has been gaining attention in the dermatology literature since 2018. The logic behind it is deceptively simple. Instead of counting “not relevant” answers as zeros, the DLQI-R rescales the questionnaire so that only the items the patient actually answered contribute to the final score. Mathematically, the revised score is calculated as the original DLQI multiplied by ten and divided by ten minus the number of “not relevant” responses. If a patient skips two questions as irrelevant, their raw score is boosted by a factor of ten-eighths, or 1.25. The idea is that a patient who finds several questions irrelevant should not be penalized for it, and their disease burden should be estimated from the domains that genuinely apply to them.

Earlier work suggested this rescaling could matter a great deal. Studies in psoriasis, pemphigus, and morphea found that DLQI-R scoring improved the discriminatory power of the questionnaire, meaning it did a better job of distinguishing patients with different levels of disease burden. Other analyses showed that a high proportion of psoriasis patients give at least one “not relevant” response, raising the possibility of systematic biases in treatment decisions, since DLQI scores are often used to determine eligibility for expensive biologic therapies. A detailed examination of “not relevant” responses in psoriasis published in 2018 flagged exactly this concern, and a 2019 study of United States patients confirmed that these responses measurably influence DLQI values in real-world populations.

Against this backdrop, dermatologists Gülsün Hazan Tabak of Sincan Training and Research Hospital in Ankara and Neslihan Demirel Öğüt of Uşak University in Turkey designed a study to ask whether the DLQI-R truly outperforms the original DLQI when both are compared against objective measures of disease severity. They enrolled 150 adult patients with active psoriasis and 150 patients with chronic urticaria, all diagnosed by a dermatologist. To ensure that every participant had measurable disease activity at the time of assessment, patients whose psoriasis or urticaria activity scores were zero were excluded from the analysis. The final psoriasis group comprised 72 women, or 64 percent, and 39 men, or 36 percent, while the chronic urticaria group included 65 women, or 73 percent, and 24 men, or 27 percent.

Each patient completed the standard DLQI questionnaire, from which the researchers also derived the DLQI-R score using the rescaling formula. For psoriasis patients, disease severity was quantified with the Psoriasis Area and Severity Index, or PASI, a composite measure that scores the redness, thickness, and scaling of lesions across four body regions and weights those scores by the extent of involvement. For urticaria patients, severity was captured with the Urticaria Activity Score over the previous seven days, known as UAS7, which sums daily assessments of the number of wheals and the intensity of itching across a week to yield a weekly activity total. These clinician-graded and patient-recorded severity measures served as the benchmarks against which both quality-of-life scores were judged.

The statistical approach was straightforward and appropriate for the data type. Because DLQI, DLQI-R, PASI, and UAS7 values are not normally distributed in most clinical samples, the researchers used Spearman correlation analysis, a non-parametric method that assesses how well the ranks of two variables move together rather than assuming a linear relationship. Spearman coefficients range from minus one to plus one, with values approaching one indicating that patients with higher disease severity consistently report higher quality-of-life impairment. The team first checked how closely the two questionnaires tracked each other, then compared how strongly each one correlated with the objective severity measure in each disease group.

The first finding was unsurprising: the DLQI and DLQI-R are nearly interchangeable. In the psoriasis group, the two scores showed a strong positive correlation with a Spearman coefficient of 0.981, and in the chronic urticaria group the coefficient was even higher at 0.989, both statistically significant at p less than 0.001. In other words, across these 300 patients, knowing a patient’s DLQI score tells you almost exactly what their DLQI-R score would be. The rescaling formula changes the absolute numbers, but it rarely changes where a patient stands relative to their peers.

The second finding was the one that defied expectations. In the psoriasis group, the correlation between DLQI and PASI was 0.423, while the correlation between DLQI-R and PASI was 0.416, a difference so small it carries no practical meaning. The chronic urticaria group told the same story: DLQI correlated with UAS7 at 0.623 and DLQI-R at 0.608. Contrary to the hypothesis that motivated the study, the DLQI-R was not found to be superior to the original DLQI in assessing disease-related quality of life in either condition. The proposed fix, designed to correct an underestimation of disease burden, did not translate into a stronger relationship with measured disease severity in these two patient populations.

Why might the rescaling fail to deliver an advantage here? One plausible explanation lies in the nature of the correlation itself. A moderate correlation of around 0.42 between PASI and either quality-of-life score reflects a well-known reality of psoriasis: how badly skin looks and how badly it disrupts life are related but far from identical. Visible plaques on covered skin may barely trouble one patient, while mild involvement on the hands or face can devastate another. In that context, a rescaling that boosts scores for patients with many “not relevant” answers may simply redistribute small differences without improving the fundamental alignment between clinical severity and lived experience. The very high correlation between the two questionnaires also suggests that the number of “not relevant” responses, and the corrections applied for them, were too uniform across patients to create meaningful separation between the instruments.

The study’s authors draw a different practical conclusion from their data. Given the high proportion of patients who provided at least one “not relevant” response, they argue that disease-specific health-related quality of life instruments may complement the DLQI by capturing aspects of quality of life that the generic DLQI items do not adequately address. Tools designed specifically for psoriasis or for chronic urticaria can probe the domains that matter most in each condition, from itch intensity and sleep disruption in urticaria to the emotional and social burden of visible plaques in psoriasis. The researchers suggest that adopting disease-specific quality-of-life scales in routine clinical practice would be advantageous, rather than relying solely on a generic instrument or its rescaled variant. The study, approved by the Ethics Committee of Uşak University and conducted in accordance with the Declaration of Helsinki, adds an important cautionary note to a debate that has been building in dermatology for years: before abandoning a familiar measure for a mathematically elegant correction, clinicians should demand evidence that the correction actually improves what matters, and in psoriasis and chronic urticaria, at least, the evidence now says it does not.

Subject of Research: Comparison of DLQI and DLQI-Relevant quality-of-life scores against disease severity in psoriasis and chronic urticaria

Article Title: The relationship between DLQI and DLQI-R scores and disease severity in patients with active psoriasis and chronic urticaria: a cross-sectional observational study

Article References: Tabak, G. H., & Demirel Öğüt, N. (2026). The relationship between DLQI and DLQI-R scores and disease severity in patients with active psoriasis and chronic urticaria: a cross-sectional observational study. Archives of Dermatological Research, 318(1), Article 420. https://doi.org/10.1007/s00403-026-04897-w

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04897-w

Keywords: Dermatology Life Quality Index, DLQI-R, psoriasis, chronic urticaria, PASI, UAS7, health-related quality of life, disease severity, Spearman correlation, cross-sectional study, dermatology, patient-reported outcomes

The study, led by Olivia Babich of the University of Pittsburgh School of Medicine with colleagues including senior author Sonal Choudhary of the University of Pittsburgh Medical Center, set out to fill a persistent gap. Despite the prevalence and impact of hidradenitis suppurativa, the authors note, there remains a paucity of patient-oriented data directly analyzing demographic and socioeconomic factors and their association with quality of life. Much of the existing literature focuses on clinical measures, comorbidities, or treatment response, leaving the lived texture of the disease, the missed buses, the confusing leaflets, the appointments that never happen, largely unmeasured.

To capture that texture, the team consecutively identified patients with hidradenitis suppurativa and sent them a digital survey covering their experiences living with the condition, their assessment of treatment success, and their interactions with the healthcare system. The instrument incorporated the Dermatology Life Quality Index, a validated questionnaire that scores the impact of skin disease across daily activities, symptoms, and emotional wellbeing. Crucially, the researchers did not rely on self-report alone: they also extracted electronic medical record data, including each participant’s Hurley stage, the standard three-tier system clinicians use to grade hidradenitis suppurativa severity from localized nodules to widespread abscesses, scarring, and interconnected sinus tracts.

The recruitment numbers tell their own story about the burden of the disease. Of 343 patients approached between January 2022 and January 2025, 102 completed the survey, a response rate of 29.7 percent. The final cohort had a mean age of 38.6 years with a standard deviation of 11.1, and only 12 participants, or 11.8 percent, were male, a distribution consistent with the condition’s well-documented female predominance. The survey was administered through a research electronic data capture platform, and the study received a formal exemption from the University of Pittsburgh Institutional Review Board on August 4, 2023, with all participants providing written informed consent before taking part.

The statistical heart of the paper lies in its univariate and multivariate analyses, which tested associations between patient variables and disease outcomes. Participants whose Dermatology Life Quality Index scores exceeded 10, a threshold generally interpreted as indicating a severe effect of skin disease on life quality, shared a distinctive profile. They were typically diagnosed at a younger age, with an odds ratio of 0.957 per year of age at diagnosis, a 95 percent confidence interval of 0.916 to 0.999, and a p value of 0.047. In practical terms, each additional year of age at diagnosis slightly reduced the odds of falling into the high-burden group, implying that earlier onset marks a more disruptive disease trajectory.

Two socioeconomic variables stood out even more sharply. Patients who reported concerns regarding transportation access had nearly five and a half times the odds of a Dermatology Life Quality Index above 10, with an odds ratio of 5.471 and a 95 percent confidence interval of 1.440 to 20.783, reaching significance at p equals 0.013. And those who more often required assistance when reading written material from their doctor or pharmacy had more than six times the odds, an odds ratio of 6.298 with a confidence interval of 1.194 to 33.238 and a p value of 0.030. Wide confidence intervals reflect the modest sample size, but the direction of both associations is consistent with a broader literature linking social determinants of health to outcomes in chronic inflammatory disease.

Perhaps the most provocative finding is what did not predict quality of life. Higher Dermatology Life Quality Index scores, the authors report, were significantly associated with several participant factors, including poorer understanding of written material from doctors or pharmacies, lower attendance rates at scheduled medical appointments, and lack of access to reliable transportation. Hurley stages, by contrast, were not. In other words, the anatomical severity a dermatologist documents in the chart did not track with how devastating patients found the disease, while the practical frictions of navigating care did. For a condition in which flares are painful, recurrent, and often hidden beneath clothing, that disconnect between clinical staging and patient experience carries real weight.

The finding resonates with a growing body of work on hidradenitis suppurativa’s wider footprint. Recent studies have linked the disease to cardiometabolic comorbidities in diverse safety-net populations, to psychiatric disease in systematic reviews and meta-analyses, and to markedly increased healthcare utilization among patients of color, where racial disparities in management have been documented at single institutions. Diagnostic delay remains, as one 2024 review put it, still an unsolved problem, and the new result adds a mechanistic hint: if patients struggle to read discharge instructions or cannot count on a ride to clinic, the delays and missed appointments that worsen outcomes may begin long before any biologic therapy is chosen.

The study’s methodology deserves both credit and caution. Pairing patient-reported survey responses with electronic medical record data, including physician-assigned Hurley stages, is a methodological strength that many quality-of-life surveys lack, anchoring subjective burden to objective clinical documentation. But the investigators are candid about the limits. The single-center design, the modest sample of 102 respondents, and the possibility that sicker or more frustrated patients were more motivated to respond all constrain generalizability. The authors explicitly describe the work as exploratory and hypothesis-generating in nature, and they caution that additional research involving patient-reported outcomes and relationships between patient factors and disease course is needed to aid in the development of more effective and comprehensive care plans.

Even so, the message for clinicians is hard to ignore. Screening a hidradenitis suppurativa patient for transportation insecurity or low health literacy may, according to these data, tell you more about their quality of life than another glance at their skin. The research was supported by the University of Pittsburgh Clinical and Translational Science Institute through the National Institutes of Health Clinical and Translational Science Award program under grant UL1 TR001857, and the team suggests that simple interventions, plain-language written materials, transportation assistance, and flexible scheduling, could be tested as complements to medical therapy. For a disease that has long been measured in nodules and tracts, the new survey argues that the most meaningful severity score may be written not on the skin, but in the obstacles a patient faces on the way to care.

Subject of Research: Associations between demographic, socioeconomic, and medical factors and disease severity and quality of life in hidradenitis suppurativa

Article Title: Factors related to clinical severity and quality of life in hidradenitis suppurativa: findings from a cross-sectional digital survey

Article References: Babich, O., DeVore, S., Chang, S. J., Sadur, A., Tariq, Z., Shah, V. K., & Choudhary, S. (2026). Factors related to clinical severity and quality of life in hidradenitis suppurativa: findings from a cross-sectional digital survey. Archives of Dermatological Research, 318(1), Article 477. https://doi.org/10.1007/s00403-026-04981-1

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04981-1

Keywords: hidradenitis suppurativa, quality of life, Dermatology Life Quality Index, Hurley stage, cross-sectional survey, patient-reported outcomes, social determinants of health, health literacy, transportation barriers, dermatology, diagnostic delay, chronic inflammatory skin disease